Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Ari Green, MD, University of California, San Francisco, discusses the promising results observed in current remyelination trials in multiple sclerosis (MS) and the patient-specific features that may influence therapy outcomes.
Mitzi Joi Williams, MD, of Joi Life Wellness Multiple Sclerosis (MS) Center, lists challenges in recruiting and retaining minority populations for clinical trials and discusses ways to ensure clinical trial accessibility.
Krystyn Van Vliet, PhD, of Cornell University, discusses the scalability of 3D platforms in multiple sclerosis (MS) drug discovery and compares their costs with those of other drug discovery methods.